{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-24-000114","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.073971+00:00","generated_at":"2026-05-30T00:37:11.516386+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Senti Bio Q3 net loss $28.9M; cash $10.5M; SENTI-202 data expected Q4 2024","bullets":["Net loss $28.9M ($6.31 per share); R&D spend $8.7M (down from $9.1M YoY).","Cash and equivalents $10.5M at Sept 30; subsequent $2.5M CIRM tranche received.","Phase 1 enrollment of SENTI-202 ongoing; initial safety/efficacy data on track by year-end.","CIRM grant total $8.0M; $4.9M received through Nov 2024.","SENTI-301A pilot trial with Celest expects first patient dosing in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-24-000114","json":"https://secwatch.observer/filing/0001854270-24-000114.json","markdown":"https://secwatch.observer/filing/0001854270-24-000114.md","text":"https://secwatch.observer/filing/0001854270-24-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/0001854270-24-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/snti-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:37:11.516386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}